Status:
COMPLETED
HaemoCerTM Application in Breast Cancer Surgery
Lead Sponsor:
Medical University of Vienna
Conditions:
Breast Neoplasm Female
Mastectomy, Segmental
Eligibility:
FEMALE
18-99 years
Phase:
NA
Brief Summary
HaemoCer is a hemostatic agent to control bleedings during surgical procedures by accelerating natural hemostasis and is frequently applied during breast conserving surgery in women with breast cancer...
Eligibility Criteria
Inclusion
- Patients with breast cancer undergoing breast-conserving surgery
- No previous breast-conserving surgery on the same site
- ≥ 18 years age
- no current pregnancy
- Informed consent
Exclusion
- Patients with previous breast-conserving surgery on the same site
- \-
Key Trial Info
Start Date :
October 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT04811378
Start Date
October 5 2017
End Date
March 1 2021
Last Update
September 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090